In a previous study, treating ovarian cancer [27] and rhabdomyosarcoma cells [34] with anti-GP130 antibody or GP130 shRNA was found to inhibit STAT3 phosphorylation and/or cell survival, which is consistent with the results of this study. This evidence concerns the gene STAT3 and ovarian carcinoma.